Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system

CLEVELAND — Whether vagal nerve stimulation improved outcomes for heart failure patients with reduced ejection fraction (HFrEF) remained unclear after ANTHEM-HFrEF was terminated early, with

Ab­stracts for the Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy are out, with new da­ta from Pfiz­er’s ADC, Nim­bus Ther­a­peu­tics’ im­muno-on­col­o­gy drug, Nu­va­tion Bio’s ROS1 in­hibitor and